Text-only version of this email
Quince Therapeutics
August 15, 2024 7:00 AM EDTQuince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data
Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
View this release →
Or click here to view all releases.
Show all